Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany

• Krischan Braitsch,
• Laura K. Schmalbrock,
• Paul Jung,
• Irmgard Bumeder,
• Philipp Kiewe,
• Judith S. Hecker,
• Mareike Verbeek,
• Jörg Westermann,
• Lars Bullinger,
• Ulrich Keller,
• Florian Bassermann,
• Jan Krönke,
• Katharina S. Götze,
• Kathrin Rieger

Affiliations

Krischan Braitsch

1 Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany

Laura K. Schmalbrock

2 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany

Paul Jung

2 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany

Irmgard Bumeder

4 Praxis und Tagesklinik für Hämatologie und internistische Onkologie, Munich, Germany

Philipp Kiewe

5 Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany

Judith S. Hecker

1 Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany

Mareike Verbeek

1 Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany

Jörg Westermann

6 Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany

Lars Bullinger

3 Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Germany

Ulrich Keller

2 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany

Florian Bassermann

1 Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany

Jan Krönke

2 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany

Katharina S. Götze

1 Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany

Kathrin Rieger

2 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany